Company · alector-inc-e310897d
Alector Inc.
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Alector Inc. Companies, record alector-inc-e310897d. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/alector-inc-e310897d
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Alector Inc.
- Trials
- 12
- As lead sponsor
- 10
- As collaborator
- 2
- Recruiting
- 1
- Active, recruiting or not
- 1
- Completed
- 6
- Stopped early, withdrawn or suspended
- 5
- Posted results
- 5
- Trials by phase
- Phase 1 4, Phase 2 6, Phase 3 2
- Drugs its trials test
- 2
- Comparisons calculated in its trials
- 4
- First trial registered
- 2018-08-17
- Last update
- 2026-09-21
Source ClinicalTrials.gov
Pipeline2
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| LATOZINEMAB | Phase 3 | 5 | 5 | 0 | https://conductscience.org/library/drugs/CHEMBL4650439 | Open Targets | ||
| OSUGACESTAT | Phase 1 | 1 | 1 | 0 | https://conductscience.org/library/drugs/CHEMBL4297269 | Open Targets |
Trials12
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | Collaborator | Phase 2 | Recruiting | Interventional | 220 | 2025-08-14 | https://conductscience.org/library/trials/NCT07105709 | ClinicalTrials.gov | ||
| NCT06111014 | Continuation Study for Latozinemab | Lead sponsor | Phase 3 | Terminated | Interventional | 17 | 2023-12-08 | LATOZINEMAB | https://conductscience.org/library/trials/NCT06111014 | ClinicalTrials.gov | |
| NCT06079190 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease | Collaborator | Phase 2 | Terminated | Interventional | 367 | 2023-10-20 | https://conductscience.org/library/trials/NCT06079190 | ClinicalTrials.gov | ||
| NCT05744401 | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease | Lead sponsor | Phase 2 | Terminated | Interventional | 197 | 2023-01-04 | 2026-02-25 | https://conductscience.org/library/trials/NCT05744401 | ClinicalTrials.gov | |
| NCT05053035 | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | Lead sponsor | Phase 2 | Terminated | Interventional | 5 | 2021-09-02 | 2025-06-18 | LATOZINEMAB | https://conductscience.org/library/trials/NCT05053035 | ClinicalTrials.gov |
| NCT04592874 | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease | Lead sponsor | Phase 2 | Completed | Interventional | 356 | 2021-01-22 | 2025-10-29 | https://conductscience.org/library/trials/NCT04592874 | ClinicalTrials.gov | |
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Lead sponsor | Phase 3 | Terminated | Interventional | 119 | 2020-07-23 | 2026-09-21 | LATOZINEMAB | https://conductscience.org/library/trials/NCT04374136 | ClinicalTrials.gov |
| NCT04111666 | A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 | Lead sponsor | Phase 1 | Completed | Interventional | 88 | 2019-12-14 | OSUGACESTAT | https://conductscience.org/library/trials/NCT04111666 | ClinicalTrials.gov | |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Lead sponsor | Phase 2 | Completed | Interventional | 33 | 2019-09-27 | 2025-08-22 | LATOZINEMAB | https://conductscience.org/library/trials/NCT03987295 | ClinicalTrials.gov |
| NCT03822208 | First in Human Study for Safety and Tolerability of AL003. | Lead sponsor | Phase 1 | Completed | Interventional | 54 | 2019-03-29 | https://conductscience.org/library/trials/NCT03822208 | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsConditions6
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Healthy | 4 |
| Alzheimer Disease | 3 |
| Alzheimer's Disease | 3 |
| Frontotemporal Dementia | 3 |
| Amyotrophic Lateral Sclerosis | 1 |
| Neurodegenerative Diseases | 1 |
Source ClinicalTrials.gov
Partners2
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| GlaxoSmithKline | Industry | 4 | https://conductscience.org/library/companies/glaxosmithkline-b97dbf35 | ClinicalTrials.gov |
| AbbVie | Industry | 1 | https://conductscience.org/library/companies/abbvie-3ab2fef9 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/alector-inc-e310897d
GET https://conductscience.org/api/companies/v1/alector-inc-e310897d/pipeline